PDF(Pubmed)
Abstract：
Secukinumab (Cosentyx), an interleukin-17A-targeting biological agent, is commonly prescribed for psoriasis, psoriatic arthritis, and spondyloarthritis (SpA). Alopecia areata (AA), an IL-17-mediated autoimmune disorder characterized by nonscarring hair loss, particularly in an ophiasis pattern, represents a rare adverse effect associated with secukinumab therapy. We present a case of a 46-year-old female with SpA undergoing secukinumab treatment, who developed an ophiasis pattern of AA, subsequently experiencing regrowth upon medication discontinuation. The patient\'s clinical course and treatment response are detailed, alongside a discussion on the potential pathophysiological mechanisms underlying secukinumab-induced AA. Additionally, we provide a review of existing literature, discussing similar cases and proposing hypotheses on the immunological basis of this adverse event. This report underscores the importance of recognizing and managing secukinumab-induced AA, highlighting the need for further investigation and tailored therapeutic approaches in affected patients.
摘要：
Secukinumab（Cosentyx），一种白细胞介素-17A靶向生物制剂,通常是牛皮癣的处方，银屑病关节炎,和脊柱关节炎（SpA）。斑秃(AA),一种以无疤痕脱发为特征的IL-17介导的自身免疫性疾病，特别是在一种蛇形模式中，代表与苏金单抗治疗相关的罕见不良反应。我们介绍了一例46岁的女性SpA正在接受苏金单抗治疗，他发展出了AA的蛇虫病模式，随后在停药后经历再生。患者的临床过程和治疗反应是详细的，同时讨论了苏金单抗诱导AA的潜在病理生理机制。此外,我们提供了对现有文献的回顾，讨论类似的病例，并在此不良事件的免疫学基础上提出假设。本报告强调了识别和管理苏金单抗诱导的AA的重要性，强调需要进一步调查和量身定制的治疗方法在受影响的患者。
